Nivolumab or nivolumab plus ipilimumab in patients with relapsed malignant pleural mesothelioma (IFCT-1501 MAPS2): a multicentre, open-label, randomised, non-comparative, phase 2 trial-Reference-Cited by-同舟云学术

Nivolumab or nivolumab plus ipilimumab in patients with relapsed malignant pleural mesothelioma (IFCT-1501 MAPS2): a multicentre, open-label, randomised, non-comparative, phase 2 trial

Published:2019-02 Issue:2 Volume:20 Page:239-253
ISSN:1470-2045
Container-title:The Lancet Oncology
language:en
Short-container-title:The Lancet Oncology

Author:

Scherpereel Arnaud,Mazieres Julien,Greillier Laurent,Lantuejoul Sylvie,Dô Pascal,Bylicki Olivier,Monnet Isabelle,Corre Romain,Audigier-Valette Clarisse,Locatelli-Sanchez Myriam,Molinier Olivier,Guisier Florian,Urban Thierry,Ligeza-Poisson Catherine,Planchard David,Amour Elodie,Morin Franck,Moro-Sibilot Denis,Zalcman Gérard,DEBIEUVRE Didier,HIRET Sandrine,CADRANEL Jacques,FRABOULET-MOREAU Séverine,CARMIER Delphine

Publisher

Elsevier BV

Subject

Oncology

Reference36 articles.

1. Malignant mesothelioma;Robinson;Lancet,2005

2. Guidelines of the European Respiratory Society and the European Society of Thoracic Surgeons for the management of malignant pleural mesothelioma;Scherpereel;Eur Respir J,2010

3. Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial;Zalcman;Lancet,2016

4. Malignant pleural mesothelioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up;Baas;Ann Oncol,2015

5. British Thoracic Society Guideline for the investigation and management of malignant pleural mesothelioma;Woolhouse;Thorax,2018

Cited by 362 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Unleashing precision: A review of targeted approaches in pleural mesothelioma;Critical Reviews in Oncology/Hematology;2024-11

2. Survival prediction in peritoneal mesothelioma: a nomogram based on SEER data and a Chinese cohort;Frontiers in Endocrinology;2024-09-06

3. Real-world safety of nivolumab in patients with malignant pleural mesothelioma in Japan: post-marketing surveillance study;Japanese Journal of Clinical Oncology;2024-09-03

4. Enhancing pancreatic cancer immunotherapy: Leveraging localized delivery strategies through the use of implantable devices and scaffolds;Journal of Controlled Release;2024-09

5. Prognostic significance of LAT1 expression in pleural mesothelioma;Heliyon;2024-09